Renal denervation for resistant hypertension and beyond

Area of Science:

• Cardiology
• Nephrology
• Medical Devices

Background:

• Over 75 million people have hypertension, with 36 million not meeting blood pressure goals.
• Resistant hypertension affects 3-6% of hypertensive individuals, often due to inadequate sympathetic nervous system inhibition.
• Current antihypertensive medications are insufficient for many patients, necessitating alternative treatments.

Purpose of the Study:

• To evaluate the efficacy and safety of renal denervation therapy for resistant hypertension.
• To explore the reasons behind the divergent results of renal denervation trials.
• To discuss the future of device-driven approaches for hypertension management.

Main Methods:

• Review of clinical trial data, including SYMPLICITY HTN-2 and SYMPLICITY HTN-3.
• Analysis of factors contributing to blood pressure control failure.
• Discussion of technical advances in targeting renal sympathetic nerves.

Main Results:

• SYMPLICITY HTN-2 demonstrated encouraging efficacy and safety of renal denervation.
• SYMPLICITY HTN-3 yielded disappointing efficacy results, contrasting with earlier findings.
• Inconsistent outcomes highlight the need for further research into renal denervation's role.

Conclusions:

• Renal denervation therapy presents a potential but complex treatment option for resistant hypertension.
• Understanding the discrepancies in trial results is crucial for optimizing future therapeutic strategies.
• Further research is needed to establish the definitive role and optimal application of renal denervation in managing resistant hypertension.